


This article was downloaded by: [Northeastern University]

On: 09 October 2014, At: 09:32

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office:

Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

New Route for Conversion of Camptothecin to 7-Ethylcamptothecin and 7-Propylcamptothecin

Xin Wang^a, Xiaojing Wu^b, Ning Cheng^b, Huiqing Zhao^a, Zhihong Gu^a & Xiang Shen^c

^a Department of Chemistry, College of Basic Medicine, Anhui Medical University, Hefei, Anhui, China

^b School of Chemical Engineering, Hefei University of Technology, Hefei, Anhui, China

^c First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China
Published online: 06 Feb 2007.

To cite this article: Xin Wang, Xiaojing Wu, Ning Cheng, Huiqing Zhao, Zhihong Gu & Xiang Shen (2007) New Route for Conversion of Camptothecin to 7-Ethylcamptothecin and 7-Propylcamptothecin, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 37:3, 519-523, DOI: [10.1080/00397910601038723](https://doi.org/10.1080/00397910601038723)

To link to this article: <http://dx.doi.org/10.1080/00397910601038723>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

New Route for Conversion of Camptothecin to 7-Ethylcamptothecin and 7-Propylcamptothecin

Xin Wang

Department of Chemistry, College of Basic Medicine, Anhui Medical
University, Hefei, Anhui, China

Xiaojing Wu and Ning Cheng

School of Chemical Engineering, Hefei University of Technology,
Hefei, Anhui, China

Huiqing Zhao and Zhihong Gu

Department of Chemistry, College of Basic Medicine, Anhui Medical
University, Hefei, Anhui, China

Xiang Shen

First Affiliated Hospital, Anhui Medical University,
Hefei, Anhui, China

Abstract: In this article, a new route for conversion of camptothecin to 7-ethylcamptothecin and 7-propylcamptothecin is described. Compared with previous reports, the reaction time of the new synthetic route was greatly shortened to 30 min, and the products were obtained in high yield.

Keywords: camptothecin, 7-ethylcamptothecin, high yield, new route, 7-propylcamptothecin

Received May 16, 2006

Address correspondence to Xiaojing Wu, School of Chemical Engineering, Hefei University of Technology, Hefei, Anhui 230009, China. E-mail: wuxiaojing@ustc.edu

INTRODUCTION

Camptothecin (CPT), a cytotoxic alkaloid first isolated from *Camptotheca acuminata* by Wall and his coworkers in 1966, was shown to have strong antitumor activity against L₁₂₁₀ leukemia and Walker 256 carcinosarcoma models.^[1,2] The unique mechanism of action that camptothecin inhibits, topoisomerase I, has revived the interest in CPT and its analogues as antitumor agents.^[3] A lot of analogues and derivatives of CPT were prepared. Among these, Topotecan and Irinotecan received FDA approval, and some other are in clinical development.^[4]

7-Ethyl-10-hydroxycamptothecin (SN-38) and 7-propyl-10-hydroxycamptothecin were synthesized by Sawada et al.^[5,6] SN-38 is a metabolite of Irinotecan, which undergoes deesterification in *vivo*.^[5] 7-Propyl-10-hydroxycamptothecin was also more potent than CPT.^[6] The route of synthesizing 7-ethylcamptothecin is important in the synthesis of SN-38: 7-propylcamptothecin to 7-propyl-10-hydroxycamptothecin.

According to the method of Sawada et al.^[5,6] CPT was treated with FeSO₄ · 7H₂O, CH₃CH₂CHO (or CH₃CH₂CH₂CHO), and H₂O₂ in H₂SO₄ to obtain the product of 7-ethylcamptothecin (or 7-propylcamptothecin). But it was pointed out by You et al.^[7] that the yield was low when this method was used to synthesize 7-ethylcamptothecin.

To improve the yield, You et al. added acetic acid to obtain a homogeneous system (yield: 54%). Lei et al.^[8] also studied this reaction; the yield only reached 70%. Wang et al.^[9] studied the reaction of synthesizing 7-propylcamptothecin, and the product was obtained in 65% yield.


We found a new route for conversion of camptothecin to 7-ethylcamptothecin and 7-propylcamptothecin; hydroperoxide was used instead of CH₃CH₂CHO (or CH₃CH₂CH₂CHO) and H₂O₂. The present procedure offers several advantages including much higher yield (7-ethylcamptothecin in 83.3% and 7-propylcamptothecin in 73.6% yields), short reaction time (within 30 min to complete the reaction), and the near completeness of the reaction.

Hydroperoxide has been prepared with ordinary method as shown in Scheme 1. Then compounds **1**, **2** were used to get 7-ethylcamptothecin and 7-propylcamptothecin (Scheme 2).

EXPERIMENTAL

General Procedure

Camptothecin (0.2 g, 0.58 mmol) was suspended in a mixture of acetic acid (2.0 ml) and H₂SO₄ (0.6 ml). After several minutes, a homogeneous system was obtained. Then FeSO₄ · 7H₂O (0.42 g, 1.5 mmol) and H₂O (1.8 ml) were added successively. After cooling to 2°C, hydroperoxidically (0.8 ml)




Scheme 1.

was added dropwise. The mixture was stirred for 30 min at 0°C and was then poured into ice water. The suspension was extracted with CHCl₃ (4 × 20 ml), and the solvent was removed under reduce pressure. The residue was purified through column chromatography of silica gel with CHCl₃ as elute.

Data

7-Ethylcamptothecin: Yellow powder (0.18 g), yield: 83.3%, mp: 259–261°C. IR (KBR): ν_{max} : 3430, 1750, 1653, 1598 cm⁻¹. ¹H NMR (CDCl₃): δ : 1.03 (3H, t, $J = 6.90$ Hz, C18-methyl protons), 1.43 (3H, t, $J = 6.90$ Hz, CH₃CH₂-), 1.89 (2H, m, C19-methylene protons), 3.20 (2H, q, CH₃CH₂-), 5.26 (2H, s, C5-methylene protons), 5.28–5.77 (2H, dd, $J = 16.20$ Hz, C-17 methylene protons), 7.71 (1H, t, $J = 7.59$ Hz, C10-H), 7.82 (1H, s, C14-H), 7.80 (1H, t, $J = 7.50$ Hz, C11-H), 8.13 (1H, d, $J = 7.80$ Hz, C9-H), 8.23 (1H, d, $J = 8.10$ Hz, C12-H). Anal calcd. for C₂₂H₂₀N₂O₄: C, 70.20; H, 5.36; N, 7.44%. Found: C, 70.10; H, 5.30; N, 7.40%. HRMS (EI+): m/z calcd. for C₂₂H₂₀N₂O₄; 376.1423; found: 376.1419.

7-Propylcamptothecin: Yellow powder (0.165 g), yield: 73.6%, mp: 232–233°C. IR (KBr): ν_{max} : 3430, 1745, 1650, 1600 cm⁻¹. ¹H NMR (CDCl₃): δ : 0.88–1.13 (8H, C19-methyl protons, CH₃CH₂CH₂-), 1.92 (2H, m, C18-methylene protons), 3.18 (2H, t, $J = 7.56$ Hz, CH₃CH₂CH₂-), 5.28 (2H, s, C5-methylene protons), 5.29–5.79 (2H, dd, $J = 16.32$ Hz, C-17 methylene protons), 7.71 (1H, t, $J = 7.59$ Hz, C10-H), 7.72 (1H, s, C14-H), 7.81 (1H, t, $J = 7.29$ Hz, C11-H), 8.12 (1H, d, $J = 8.34$ Hz, C9-H), 8.26 (1H, d, $J = 8.4$ Hz, C12-H). Anal calcd. for C₂₃H₂₂N₂O₄: C, 70.75; H, 5.68; N, 7.44%.




Scheme 2.

7.18%. Found: C, 70.60; H, 5.60; N, 7.10%. HRMS (EI+): m/z calcd. for $C_{23}H_{22}N_2O_4$: 390.1580; found: 390.1587


DISCUSSION

According to the literature,^[8,10] alkylation in position 7 of CPT in acidic media is probably a radical mechanism.


When hydroperoxide was used with transition-metal salt, the corresponding triple-alkoxyl radicals were produced^[11]



As a common fragmentation, triple-alkoxyl radical can split into alkyl radical and acetone.^[12]



The ethyl (propyl) radical formed acted with CPT to generate the 7-ethyl-camptothecin (7-propylcamptothecin) species as shown in 3.^[8,10]



In addition, it is very important to add acetic acid to the solvent system because that will improve the solubility of CPT remarkably and accordingly result in a much higher yield. The order of adding materials and the usage of H_2SO_4 and $FeSO_4 \cdot 7H_2O$ are important too and deeply affect the reaction course. For example, when we added 0.15 g of $FeSO_4 \cdot 7H_2O$ to

the system, the yield was low. In contrast, when 0.42 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ was added to the system, the reaction finished completely.

REFERENCES

1. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; Mcphail, A. T.; Sim, G. A. Plant antitumor agents: The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata*. *J. Am. Chem. Soc.* **1966**, (88), 3888–3890.
2. Muggia, F. M.; Creaveh, D. J.; Hansen, H.; Cohen, M. H.; Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. *Cancer Chemother. Rep.* **1972**, 56, 515.
3. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. *J. Biol. Chem.* **1985**, 260, 14873–14878.
4. Pan, X. D.; Wang, C. Y. Current status of camptothecin derivatives as natural antitumor agents. *Acta. Pharm. Sin.* **2003**, 38, 715–720.
5. Sawada, S.; Okajima, S.; Aiyama, R.; Nokata, K.; Furuta, T.; Yokukora, T.; Sugino, E.; Yamaguchi, K.; Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. *Chem. Pharm. Bull.* **1991**, 39, 1446.
6. Sawada, S.; Matsuoka, S.; Nokata, K.; Nagata, H.; Furuta, T.; Yokokura, T.; Miyasaka, T. Synthesis and antitumor activity of 20 (S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins. *Chem. Pharm. Bull.* **1991**, 39, 3183.
7. You, Q. D.; Sun, P. Y. Synthesis of 7-ethyl-10-hydroxycamptothecin. *Chin. J. Pharm.* **1994**, 25, 250–251.
8. Lei, Y. J.; Zhu, C. H.; Wang, Z. Q.; Liu, H. Synthesis of 7-ethyl-10-hydroxycamptothecin and proposed reaction mechanism. *Chem. Res. Chinese. U.* **2001**, 17, 69–72.
9. Wang, R. B.; Lei, Y. I.; Liu, H. A study on synthesis of 20(s)-7-propyl-10-hydroxycamptothecin. *App. Chem. Industry* **2001**, 30 (4), 23–28.
10. Minisci, F.; Porta, O. *Adv. Heterocycl. Chem*; Academic Press: New York, 1974; Vol. 16, p. 123.
11. Richardson, W. H. P. The cobalt(II) decomposition of *t*-butyl hydroperoxide. *J. Am. Chem. Soc.* **1965**, 87, 247.
12. Zhang, Y. M. *Physical Organic-Chemistry*; Shanghai Press of Science and Technology: Shanghai, 2001, pp. 264–280.